| Data | Hora | Fonte | Título | Código | Companhia |
| 11/04/2019 | 15:00 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 09/04/2018 | 17:54 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 22/03/2018 | 15:12 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(b) (15-12b) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 22/03/2018 | 07:01 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 19/03/2018 | 16:17 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 13/03/2018 | 19:16 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 09/03/2018 | 19:03 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 09/03/2018 | 11:53 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 09/03/2018 | 11:50 | Edgar (US Regulatory) | Post-effective Amendment to Proposed Securities Act Rule 462(b) Registration Statement (pos462b) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 09/03/2018 | 11:45 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 09/03/2018 | 11:18 | Edgar (US Regulatory) | (25-NSE) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 09/03/2018 | 08:18 | Edgar (US Regulatory) | Amended Statement of Ownership: Solicitation (sc 14d9/a) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 09/03/2018 | 08:13 | Edgar (US Regulatory) | Amended Tender Offer Statement by Third Party (sc To-t/a) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 08/03/2018 | 18:52 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 16/02/2018 | 11:00 | Business Wire | Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 08/02/2018 | 20:39 | Business Wire | Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc. | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 08/02/2018 | 20:29 | Edgar (US Regulatory) | Statement of Ownership: Solicitation (sc 14d9) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 08/02/2018 | 20:28 | Edgar (US Regulatory) | Tender Offer Statement by Third Party (sc To-t) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 07/02/2018 | 20:26 | Edgar (US Regulatory) | Written Communication Relating to an Issuer or Third Party (sc To-c) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 01/02/2018 | 12:31 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 31/01/2018 | 11:26 | PR Newswire (US) | Cascadian (CASC) Alert: Johnson Fistel Investigates Proposed Sale of Cascadian Therapeutics, Inc.; Is $10.00 a Fair Price for... | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 31/01/2018 | 10:23 | Edgar (US Regulatory) | Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 31/01/2018 | 09:30 | Business Wire | Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 04/01/2018 | 11:30 | GlobeNewswire Inc. | Cascadian Therapeutics Announces 2018 Outlook and Recent Progress | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 02/01/2018 | 11:30 | GlobeNewswire Inc. | Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 29/12/2017 | 19:10 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 13/12/2017 | 11:35 | GlobeNewswire Inc. | Cascadian Therapeutics Added to the Nasdaq Biotechnology Index | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 07/12/2017 | 19:05 | GlobeNewswire Inc. | Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Can... | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 08/11/2017 | 20:04 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |
| 08/11/2017 | 19:01 | GlobeNewswire Inc. | Cascadian Therapeutics Reports Third Quarter 2017 Financial Results | NASDAQ:CASC | Cascadian Therapeutics, Inc. (delisted) |